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Optimizing Hemostatic Practices:
Matching the Appropriate
Hemostat to the Clinical Situation
DEBORAH J. NEVELEFF, MBAABSTRACTAchieving hemostasis is a critical focus of clinicians working in the surgical setting,
given that uncontrolled surgical bleeding is associated with increased mortality rates
and higher costs of care. As principal members of the surgical team, perioperative
nurses are in an optimal position to plan and direct care during a bleeding event and
throughout a patient’s surgical stay. This supplement includes an assessment of
the clinical and economic effects of surgical bleeding, a thorough review of
available therapies, and a detailed comparison of these products to demonstrate
which agents are best suited for a given clinical situation. By understanding the basic
science of coagulation and hemostasis and current advances in topical hemostatic
agents, including their safety, efficacy, and judicious use, perioperative nurses
will be empowered to better assist the surgeon in optimizing patient outcomes.
AORN J 96 (November 2012) S4-S17.  AORN, Inc, 2012. http://dx.doi.org/10.
1016/j.aorn.2012.08.005
Key words: hemostasis, topical hemostats, mechanical hemostatic agents, active
hemostatic agents, flowable hemostatic agents, fibrin sealants, adhesives.Editor’s note: This article is based on a presen-
tation by Spencer Galt, MD, vascular surgeon,
Mountain Medical Vascular Specialists, Murray,
UT, and William D. Spotnitz, MD, MBA, professor
of surgery and director of the Surgical Therapeutic
Advancement Center for the Department of Surgery
at University of Virginia Health System, Charlot-
tesville, VA.
A
chieving hemostasis (ie, bleeding control)
is a critical focus of clinicians working in
the surgical setting because uncontrolled
surgical bleeding is associated with increased mor-
tality rates and higher costs.1,2 Failure to achieveS4 j AORN Journal  November 2012 Vol 96 No 5hemostasis can unnecessarily prolong the surgical
procedure, impair wound healing, increase infection
risk, and result in unanticipated exposure to blood
products if the patient needs a transfusion.1,2 A
variety of hemostatic agents tomitigate uncontrolled
bleeding are available, including topical hemostats,
sealants, and adhesives. Nevertheless, hemostasis is
not achieved in as many as 40% of surgical patients
(eg, during surgery for trauma-related injury) because
hemostatic agents are not used appropriately.3
As principal members of the surgical team,
perioperative nurses are in an optimal position to
plan and direct care during a bleeding event and
throughout a patient’s surgical experience. To havehttp://dx.doi.org/10.1016/j.aorn.2012.08.005
 AORN, Inc, 2012
NACCME SUPPLEMENT www.aornjournal.orgthe greatest effect, however, perioperative nurses
must thoroughly understand the benefits and limi-
tations of each hemostatic product so that they may
assist in matching the most appropriate agent to the
clinical situation.CONSEQUENCES OF SURGICAL
BLEEDING
According to the Centers for Disease Control and
Prevention, approximately 45 million inpatient
surgical procedures are performed in the United
States each year.4 In addition, more than 34.7
million ambulatory surgical procedures were per-
formed in 2006 alone, 19.9 million of which oc-
curred in the hospital setting.5 These procedures
represent a 300% increase from 1996 to 2006. This
increase in the number of surgical procedures being
performed will likely continue as a result of medical
advances and the increasing age of the population.5
Notably, as surgery rates escalate, the clinical and
economic consequences of uncontrolled bleeding
and transfusion also rise, thereby emphasizing
the importance of maintaining hemostasis in the
surgical setting.Clinical Implications of Surgical Bleeding
Bleeding is a major complication of surgery and
is associated with increased morbidity and mor-
tality.4,6,7 Clinical consequences of uncontrolled
bleeding include
n anemia,
n hemodynamic instability,
n hypothermia,
n hypovolemia,
n reduced oxygen delivery to tissues,
n impaired visualization of surgical field, and
n increased length of surgical time.6
In addition, surgical bleeding is associated with
the need for blood transfusion and reoperation,
which are costly and require large amounts of
clinical and staff resources.7 The risk of bleeding
and transfusion varies by procedure typedfrom
7.5% in reproductive organ surgery to 27.5% ingeneral surgery to 47.4% in cardiac surgery.3,4,6,7
Major bleeding is also associated with increased
risk of postoperative mortality (eg, as much as
20% in vascular surgery and between 30% and 40%
in trauma surgery with uncontrolled bleeding).7
Blood transfusion itself is associatedwithmultiple
risks.2 Transfusion-related acute lung injury is the
leading cause of transfusion-related morbidity and
mortality and occurs in one of every 1,000 to 5,000
plasma and red blood cell transfusions.2 Bacterial
contamination, another common transfusion-
related complication, occurs in one of every 2,000 to
3,000 platelet transfusions.2 Other clinical conse-
quences associated with transfusion include the risk
of mistransfusion (ie, one of every 12,000 to 19,000
units transfused) and viral infection (eg, less than one
of every one million units transfused).2 Additional
clinical risks include transfusion-related immuno-
modulation, circulatory overload, and complications
associated with use of red blood cells stored for
longer than 28 days (eg, limitation of oxygen
delivery, multiple organ system failure, increased
mortality).2,8
To evaluate the effect of bleeding complica-
tions and transfusion, Stokes et al3 conducted
a retrospective analysis of a hospital database.
Patients included in the analysis underwent an
inpatient procedure within a specialty of interest
(ie, cardiac, vascular, noncardiac thoracic, solid
organ, general, reproductive organ, knee or hip
replacement, spine) between 2006 and 2007. The
researchers reported that patients with bleeding-
related complications or blood product transfu-
sions required longer hospital stays compared
with patients who did not have bleeding complica-
tions (10.4 days versus 4.4 days, respectively).3
Likewise, patients with bleeding complications
or transfusions spent more time in the intensive
care unit compared with those who did not have
bleeding-related complications or transfusions
(3.3 days versus 0.5 days, respectively).3 In a
separate analysis, the number of units transfused
also was found to increase intensive care unit and
hospital stays, as well as ventilator time.2AORN Journal j S5
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Given the scope of clinical consequences associ-
ated with uncontrolled bleeding and the need for
transfusion, it is not surprising that the costs related
to bleeding complications are also substantial. For
example, according to Stokes et al,3 the incremental
cost per hospitalization associated with bleeding-
related complications ranged from just less than
$3,000 for reproductive organ surgery to more
than $17,000 for spinal surgery. Stokes et al also
compared the total hospitalization costs for patients
with bleeding-related complications or blood trans-
fusions with those for patients without a complica-
tion and, again, noted a significant increase in costs
among those with complications (Figure 1).3 Fur-
thermore, transfusion-related variable costs were
found to add considerably to the economic burden
of bleeding. These include expenses associated withFigure 1. Total hospitali
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S6 j AORN Journaln increased OR time ($1,900 to $3,150 per hour),
n postoperative hospital days ($1,280 per day),
n intensive care unit days ($3,670 per day for
patients not on a ventilator and $4,810 per day
for patients on a ventilator),
n treatment of ventilator-associated pneumonia
(approximately $17,000),
n treatment of serious postoperative infection after
orthopedic surgery (approximately $20,000), and
n repeat surgery for bleeding after cardiac surgery
(approximately $30,000).2,3
By recognizing and understanding the clinical and
economic consequences of uncontrolled bleeding
and helping to ensure the appropriate clinical
response, perioperative nurses can positively affect
both individual patient outcomes and the health
care system at large.zation costs for  
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BLEEDING
As a key member of the surgical team, the peri-
operative nurse has a major role in optimizing
hemostatic practices. Essential activities of the
perioperative nurse include
n querying the surgeon about issues related to
hemostasis at the beginning of and throughout
the procedure;
n knowing what hemostatic agents are available at
the facility;
n inquiring about what products might be needed
so that preparation time can be accommodated;
n suggesting products for use; and
n communicating with the surgeon frequently
throughout the surgical procedure.
Selecting the optimal method for achieving
hemostasis relies first on properly identifying the
nature and severity of a patient’s bleeding. Typi-
cally, when a patient presents with or develops
uncontrolled bleeding in the OR, the initial action,
time permitting, is to obtain a set of coagulation
laboratory values including
n prothrombin time/international normalized
ratio,
n activated partial thromboplastin time,
n complete blood count with differential and
platelets,
n activated clotting time,
n fibrinogen,
n d-dimer, and
n thromboelastography.
In instances of unusual or complex coagulopathy,
consultation with a medical subspecialist (eg,
hematologist, blood blank professional) is also
recommended. These laboratory values, with or
without a specialist’s recommendation, can help
health care professionals evaluate the appropri-
ateness of various interventions. In addition to
the use of topical hemostats, sealants, and adhe-
sives, other hemostatic options include the use
of mechanical strategies, administration ofpharmacologic agents, and, in the most severe
cases, transfusion.Mechanical Strategies
Mechanical interventions are frequently used to
achieve hemostatic results and often can be effec-
tive without the use of any hemostatic products.
For example, using a finger to stop blood flow is
often a primary strategy in the surgeon’s repertoire.
Other mechanical methods commonly used to stop
bleeding include
n application of sponges, clips, or sutures and
n use of electrosurgery, laser, radio-frequency
energy, argon beam coagulation, ultrasonic
scalpel, or ultrasonic surgical aspirator.
These strategies also can be used to temporarily
slow uncontrolled bleeding while hemostatic
products, some of which have long preparation
times, are readied for the patient.Pharmacologic Agents
Pharmacologic strategies for blood conservation
are also an important tool in a surgical team’s
arsenal because these agents attenuate activation
of the hemostatic system without the clinical and
economic consequences associated with transfusion.9
Pharmacologic agents may be particularly useful in
patients with diffuse surgical bleeding or in those
with an underlying hemostatic defect. These phar-
macologic agents include
n recombinant factor VIIa,
n desamino-d-arginine vasopressin, and
n antifibrinolytics (eg, epsilon aminocaproic acid,
tranexamic acid).
These agents also may be used in conjunction with
surgical hemostatic products.9,10 The available
pharmacologic agents have varying contents and
mechanisms of action, indications, and limitations,
allowing the clinician to match the most appro-
priate agent to the clinical circumstances at hand
(Table 1).2,9,11AORN Journal j S7
Table 1. Pharmacologic Strategies for
Blood Conservation1-3
Product
Contents or 
mechanism of action Indications Concerns
• Recombinant 
factor VIIa
• Activates platelets to 
augment thrombin burst
• Refractory
hemorrhage (ie, 
surgery, trauma)
• Short-acting
• Thrombosis
• Costly
• Desmopression
acetate
• Selective V2 agonist to 
release factor VIII, von 
Willebrand factor, and 
tissue plasminogen 
activator
• Platelet 
dysfunction
• Short-acting
• Tachyphylaxis
• Increased bleeding 
risk with repeat 
doses
• Antifibrinolytics (ie, 
epsilon 
aminocaproic acid, 
tranexamic acid)
• Inhibits plasminogen 
proteases and plasmin 
and some anti-
inflammation
• Prevention of 
surgical blood loss
• Refractory 
hemorrhage
• Thrombosis,
hypotension
1. Boucher BA, Hannon TJ. Blood management: a primer for clinicians. Pharmacotherapy. 2007;27(10):1394-1411.
2. Levy JH. Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. Am J Health Syst Pharm. 
2005;62(18 Suppl 4):S15-S19.
3. Quarishy N, Bachowski G, Benjamin RJ, et al. A Compendium of Transfusion Practice Guidelines. American Red Cross. 
http://www.redcrossblood.org/sites/arc/files/pdf/Practice-Guidelines-Nov2010-Final.pdf. Accessed July 25, 2012.
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Administration of blood products typically is not
the primary responsibility of the perioperative
nurse; nonetheless, to properly assist the surgeon
and anesthesia professional in managing surgical
bleeding, it is important for the perioperative nurse
to have a broad understanding of blood products
used for transfusion. These blood products in-
clude fresh frozen plasma, platelets, prothrombin
complex concentrate, cryoprecipitate, and whole
blood. The contents of blood products differ widely;
therefore, it is essential to know how and when to
use each product.
Platelets, for example, contain thrombocytes
in plasma and are indicated when platelet levels
are less than 50 x 109/L, whereas cryoprecipitate
contains factor VIII, von Willebrand factor,
fibrinogen, and fibronectin and is indicated when
the patient’s fibrogen is less than 100 mg/mL orS8 j AORN Journalwhen the patient has von Willebrand factor defi-
ciency.11 Fresh frozen plasma contains coagulation
factors and fibrinogen in variable amounts, while
prothrombin complex concentrate contains factors II,
VII, IX, and X and prothrombin, as well as proteins
in variable amounts. Both fresh frozen plasma and
prothrombin complex concentrate are indicated
when a surgical patient who is bleeding has an
international normalized ratio greater than 1.5.11CONSIDERATIONS FOR SELECTING
TOPICAL HEMOSTATS, SEALANTS, AND
ADHESIVES
Although often used in combination with mechan-
ical strategies and pharmacologic agents, topical
hemostats, sealants, and adhesives remain a main-
stay for achieving hemostasis in surgical patients.
These products are widely used during surgery
to diffuse raw surface bleeding, oozing venous
NACCME SUPPLEMENT www.aornjournal.orgbleeding, bone bleeding, and needle-hole bleeding.12
The various products have proven efficacy and
varying safety profiles, such that the surgical team
must consider a number of factors before selecting
the optimal product, including reliability and pro-
mptness of bleeding control, ease of storage, re-
quired preparation time, and incidence of adverse
effects. By having a working knowledge of available
options, including an appreciation of each product’s
benefits and limitations, perioperative nurses can
offer their professional opinion in the surgical suite
to assist the surgeon in selecting a product that will
offer the best possible outcome for each patient.Topical Hemostats
Topical hemostatic agents (ie, mechanical, active,
flowable, fibrin sealants) achieve hemostasis by
causing blood to clot.13-15 Agents in this class vary
greatly with respect to safety, efficacy, usability,
and cost (Table 2). For this reason, it should be
noted that not every product is appropriate in
a given clinical scenario.15 Recognition of the
nuances between products can assist the perioper-
ative nurse in recommending the hemostat that is
most likely to optimize outcomes.
Mechanical hemostats. By incorporating a
hemostatic agent into an absorbable material, such as
a sponge, foam, or pad,mechanical hemostatic agents
create a barrier to blood flow and provide a surface
on which blood may clot.15 Common mechanical
hemostatic agents include porcine gelatin products
(eg, Gelfoam, Gelfoam Plus, Surgifoam), cellu-
lose products (eg, Surgicel, Surgicel FibrillarTM,
Surgicel Nu-Knit), bovine collagen products (eg,
AviteneTM sheets, Avitene UltrafoamTM collagen
sponges), and polysaccharide spheres (eg, Arısta,
Hemostase MPH, VitasureTM).13-15 Although
useful in cases of minimal bleeding, mechanical
hemostats are only appropriate for use in patients
with an intact coagulation cascade because mech-
anical hemostats rely on fibrin production to achieve
hemostasis.15,16 Mechanical agents are easy to use
because theyn are available in easy-to-open packages,
n require no special preparation or storage, and
n can be easily applied via direct pressure on the
bleeding site.15
It is important, however, to gently irrigate a mec-
hanical hemostat before it is removed to avoid
debridement of the underlying clot and resumption
of bleeding.14,15
Despite similarities in mechanisms of action and
ease of use, there are notable differences in efficacy
among mechanical hemostatic agents. For example,
bovine collagen and polysaccharide spheres are
reported to be maximally effective,17-19 followed
by porcine gelatin and oxidized regenerated cellu-
lose.20 Agents in this category are relatively in-
expensive and are typically well tolerated; only
swelling and infection are cited as possible adverse
events.9 They are often used, therefore, as a first-
line response to bleeding.15
Active hemostatics. By converting fibrinogen
to fibrin, active hemostatsdnamely the three
topical thrombin products: bovine thrombin
(Thrombin-JMI),21 pooled human plasma thrombin
(Evithrom),22 and recombinant thrombin (Reco-
throm)23dfacilitate clot formation at the bleeding
site.14-16 Active hemostatic agents are the most
commonly used adjunct hemostatic therapies in the
surgical setting, with conservative estimates indi-
cating that more than one million patients are treated
with topical thrombin application annually in the
United States.24
Each of the three thrombins may be applied to
a local bleeding site or sprayed over a larger area
of diffuse bleeding, although some preparation is
required before application.15 For example, bovine
and recombinant thrombin are stored at room
temperature in a powder form that must be recon-
stituted with a specified liquid.15 Although it must
be thawed before use, pooled human thrombin is
available in a liquid form and can be stored in a
refrigerator for as long as one month.15 Notably,
active bleeding may cause these agents to be
washed away, and thus, thrombins may be mostAORN Journal j S9
Table 2. Topical Hemostats: Comparison of 
Safety, Efficacy, Usability, and Cost1
Category Safety Efficacy Usability Cost
Mechanical
• Porcine gelatin
• Bovine collagen
• Oxidized regenerated cellulose
• Polysaccharide spheres
• Generally well tolerated
• Swelling
• Effective for 
minimal bleeding
+++ $
Active
• Bovine thrombin
• Pooled human thrombin
• Recombinant thrombin
• Antibody formation
• Possible disease 
transmission
• Effective for 
localized and 
diffuse bleeding
++ $$
Flowable
• Bovine gelatin + pooled human thrombin
•
•
•
Porcine gelatin ± thrombin
• Possible disease
transmission
• Most effective for 
localized bleeding
++ $$$
Fibrin sealant
Pooled human plasma
Individual human plasma with bovine 
collagen + bovine thrombin
Individual human plasma
• Possible disease 
transmission
• Swelling
• Antibody formation
• More effective for 
localized and 
diffuse bleeding
+ $$$
+ = most complex to prepare and use $ = least expensive
++ = relatively easy to prepare and use $$ =  moderately expensive
+++ = easiest to prepare and use $$$ = most expensive
1. Spotnitz WD, Burks S. State-of-the-art review: Hemostats, sealants, and adhesives II: update as well as how and when to use the 
components of the surgical toolbox. Clin Appl Thromb Hemost. 2010;16(5):497-514.
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absorbable gelatin sponge or powder.15 Thrombin
products should not be delivered intravascularly
because IV administration can prompt severe hy-
potension or a major anaphylactic reaction.21-23
The three available thrombin products are
functionally equivalent in terms of efficacy for
local or diffuse bleeding.15 For instance, results
of a phase 3, double-blind comparative study in
which 401 patients were randomly assigned to
receive either recombinant thrombin or bovine
thrombin revealed that 95% of patients in both
groups achieved hemostasis within 10 minutes
(95% confidence interval [CI]) and that adverse
events, laboratory abnormalities, and mortality
rates were similar between the two agents.25 Re-
searchers of another phase 3, randomized, double-
blind study reported that the proportion of patientsS10 j AORN Journalachieving hemostasis within 10 minutes of ad-
ministration was equivalent in both the human and
bovine thrombin cohorts (N ¼ 305; 97.4% versus
97.4%, respectively; 95% CI, 0.96-1.05).26 With
similar reports of adverse effects for both agents,
the two products were also noted to have com-
parable safety profiles.26
Given the similar efficacy between thrombin
products, further consideration of their differences
may help health care providers select the most
appropriate agent for a clinical situation. For in-
stance, although all three thrombin products have
been found to have similar safety profiles in clinical
trials, postmarketing surveillance has shown that
bovine thrombin has been associated with antibody
formation that can lead to immune-mediated coa-
gulopathy and death, which is why this product
carries a black box warning.8,21 As such, repeated
NACCME SUPPLEMENT www.aornjournal.orguse of bovine thrombin is not recommended be-
cause the immunologic reaction may not be evident
until a subsequent re-exposure to the product.21
By comparison, pooled human thrombin is not
susceptible to the risk of immune response like
bovine thrombin.4,9 Pooled human thrombin can,
however, be affected by blood donor shortages and
carries some risk in patients who are allergic to
human blood products.4,9 Pooled human thrombin
also presents the potential for the transmission of an
infectious disease because it is isolated from pooled
human plasma.14,15 Pooled human thrombin carries
a potential risk of transmission of viral infection
despite being screened for hepatitis B surface
antigen; HIV antibodies; hepatitis A, B, and C
viruses; and parvovirus B19.14,15
Recombinant human thrombin is not associ-
ated with antibody formation or the risk of disease
transmission because it is not derived from bovine
thrombin or pooled human plasma.14,15,21 Recom-
binant human thrombin, however, contains hamster
and snake proteins that may cause an allergic re-
action in patients who are allergic to these animal
proteins.15,23 As a result of the varying safety risks
of thrombin products, surgeons and perioperative
nurses must be aware of the patient’s clinical his-
tory (eg, allergies, possible previous exposure to
bovine thrombin) to mitigate risk.
Flowable hemostatics. Another important tool
for perioperative nurses is flowable hemostatic
agents (eg, Surgiflo, Floseal). These products
include a mechanical gelatin agent plus thrombin
that work together to obstruct the flow of blood
and convert fibrinogen to fibrin.14,15 Although
the mechanism of action is similar, Surgiflo is
a porcine gelatin available for use with bovine,
human pooled plasma, or recombinant thrombin,
whereas Floseal includes absorbable bovine
gelatin particles combined with pooled human
thrombin.14,15 Both agents are most effective
in cases of localized bleeding and can be applied
via a syringe in a downward manner, which
allows it ton be administered deep into the wound;
n adjust to wound topography;
n provide a mechanical barrier; and ultimately,
n activate blood clotting.14,15
The advantage of this is that the surgeon not only
can access the top layers of a wound, but also can
spread the product to reach irregular surfaces.15
After approximately three minutes of preparation
time, the product takes on a thick consistency,
allowing it to stay in place at the bleeding site. The
surgeon also may apply pressure directly onto the
flowable product using a saline-moistened gauze
pad to help keep it in contact with the bleeding
surface.15
There are substantial data supporting the use of
flowable hemostats in the published literature.27-29
A prospective randomized trial compared the
efficacy of Floseal and Gelfoam plus thrombin
in controlling intraoperative bleeding in patients
undergoing vascular surgery procedures.27 At
10 minutes, approximately 20% of patients who
received Gelfoam plus thrombin failed to achieve
hemostasis, compared with less than 10% of pa-
tients who received Floseal (P < .01).27 In addi-
tion, Floseal was deemed superior to Gelfoam plus
thrombin in another randomized trial, with more
Floseal recipients achieving complete bleeding
cessation within 10 minutes compared with those
in the Gelfoam plus thrombin cohort (N ¼ 93; 94%
versus 60%, respectively; P < .001).28
Although limited randomized clinical trials have
reported data to date, Surgiflo has also been proven
effective.29 In a multicenter, prospective, single-
arm study of 30 patients undergoing endoscopic
sinus surgery, researchers reported a 96.7% success
rate (95% CI, 85.1%-100%) for achieving hemo-
stasis within 10 minutes of application.29 For each
of the flowable agents, the safety profiles reflect
those of their mechanical hemostat and thrombin
components.15
Fibrin sealants. Fibrin sealantsdwhich have
separate US Food and Drug AdministrationAORN Journal j S11
November 2012 Vol 96 No 5 NEVELEFF(FDA) approvals as a topical hemostat, sealant,
and adhesivedprovide higher concentrations of
fibrinogen and thrombin than those that occur
naturally in blood, thereby allowing for clot
formation.15 Fibrin sealantsdnamely TisseelTM,
Evicel, and VitagelTMdare effective for both
local and diffuse bleeding and can be applied
using either a syringe for local bleeding or spray
with a gas-driven device for diffuse-bleeding
areas.14,15 These agents are more effective when
applied to a relatively dry surface area. They
may also be used to treat active bleeding with an
absorbable gelatin sponge, however, to allow the
surgeon to put pressure on the bleeding site.15
Fibrin sealants are widely used in clinical
practice and have been studied extensively, with
numerous references cited in the published litera-
ture evaluating the safety and efficacy of these
agents.14,30-34 Despite the volume of evidence
supporting the use of these agents, a paucity of
head-to-head comparison trials of fibrin sealants
have been completed to date.31,32,34 Recently,
however, data from a published study reported
that, based on biochemical evidence, Evicel may
allow for more rapid development of fibrin clots and
may be a stronger sealant compared with Tisseel,
suggesting that some differences may exist between
agents in this category.34 Further evaluations of
these agents are warranted to confirm the superiority
of one fibrin sealant over another.
Additional differences to consider pertain to
product preparation. All fibrin sealants are some-
what complex to prepare and use, involving a more
complicated process of reconstitution by hospital
staff members and a more skilled application
technique. For example, Tisseel is available in
both a freeze-dried and frozen form, which re-
quire thawing before application.14 Evicel comes in
a frozen form that also must be thawed before use,
either for one day in a refrigerator or one hour
at room temperature.14 Although Vitagel does not
need to be thawed, it requires the patient to provide
plasma before a procedure, which is then combined
with either bovine collagen and thrombin.14Notably,S12 j AORN Journala new patch formulation has recently been approved
and is much easier to use, but it is substantially more
expensive than other fibrin sealant options.15Sealants
Sealants (eg, fibrin sealants, polyethylene glycol
[PEG] polymers, bovine serum albumin and glu-
taraldehyde) have a hemostatic effect by forming
a barrier to blood leakage.14,15 These agents, often
used in conjunction with topical hemostats, en-
hance the surgical armamentarium and offer an
additional strategy for reducing bleeding and
transfusions. Similar to hemostats, sealants also
differ with regard to safety, efficacy, usability, and
cost (Table 3),15 all of which perioperative nurses
should familiarize themselves with to best assist
the surgical team.
Fibrin sealant. Although several fibrin sealants
are available for use as topical hemostats, only
Tisseel is FDA approved for use as a sealant.15,35
The safety profile and complexities involved in
preparing and using Tisseel are the same for both
the hemostat and sealant applications.15 Tisseel
is FDA approved as a sealant only for colostomy
procedures; special caution must be taken to prepare
the normallymoist serosal surface of the outer bowel
wall or parenchymal tissues of abdominal viscera to
ensure adequate adhesion.15
PEG polymers. An additional preparation of a
moderate-strength sealant, synthetic PEG polymers,
include three options:
n a PEG polymer plus trilysine amine approved
for dural sealing (DuraSealTM);
n a dual PEG polymer approved for vascular
sealing (Coseal); and
n a PEG polymer plus human serum albumin
(Progel) approved for intraoperative air
leaks.36-38
Each of these products forms hydrogels that seal
tissues. DuraSeal, Coseal, and Progel are moder-
ately easy to use; however, the surgical team must
account for the time required to reconstitute and
Table 3. Sealants: Comparison of Safety, 
Efficacy, Usability, and Cost1
Category Safety Efficacy Usability Cost
Fibrin sealant
• Pooled human plasma
• Possible disease transmission • Moderate + $$
Polyethylene glycol (PEG) 
polymer
• PEG + trilysine amine
• Dual PEG
• PEG + human serum 
albumin
• Swelling • Moderate ++ $$
Albumin + glutaraldehyde
• Bovine serum albumin + 
10% glutaraldehyde
• Possible tissue injury
• Emboli
• Pseudoaneurysms
• Enhanced ++ $$
+ = most complex to prepare and use $ = least expensive
++ = relatively easy to prepare and use $$ =  moderately expensive
+++ = easiest to prepare and use $$$ = most expensive
1. Spotnitz WD, Burks S. State-of-the-art review: Hemostats, sealants, and adhesives II: update as well as how and when to use the 
components of the surgical toolbox. Clin Appl Thromb Hemost. 2010;16(5):497-514.
NACCME SUPPLEMENT www.aornjournal.orgassemble the products using a dual-syringe spray
applicator.14,15,39
Use of PEG polymers is well supported in the
published literature.36,39,40 For example, results of
a multicenter randomized trial involving 148 pa-
tients revealed that, although rates of hemostasis
were similar in patients who received Coseal and
Gelfoam/thrombin (86% versus 80%, respectively;
P¼ .29), Coseal recipients achieved hemostasis
more than 10 times faster than those treated with
Gelfoam/thrombin (median time to inhibit bleeding:
16.5 seconds versus 189 seconds, respectively;
P¼ .01).40 This suggests that the PEG polymer is
at least as effective as traditional therapies and may
limit blood loss during a surgical procedure. Similar
data support the use of both DuraSeal and Progel
to mitigate cerebrospinal fluid leakage as well as
air leaks.36,39
Although PEG polymers are efficacious, con-
sideration of potential adverse events of PEG
polymers is important. Caution must be taken
to avoid liquid adhesive dripping to undesirable
locations during application because swelling is themost common safety risk, with DuraSeal swelling
up to 50% and Coseal swelling up to 400%.14,15
Accordingly, these products must be used judi-
ciously in small spaces to avoid harmful pressure
effects such as nerve compression.14 In addition,
Coseal is associated with skin sensitization in
animal studies, and DuraSeal may be associated
with a number of adverse effects (ie, wound in-
fections, cerebrospinal fluid leads, renal or neuro-
logic compromise, inflammatory reactions, delayed
wound healing).14 Finally, because Progel contains
human blood components, the potential for disease
transmissiondalthough raredexists with this
product.38
Albumin and glutaraldehyde. Bovine albumin
and glutaraldehyde (BioGlue) is a cross-linkage
between bovine serum albumin and 10% glutar-
aldehyde.15 BioGlue can be used as either a sealant
or an adhesive to achieve hemostasis. When used
as a sealant, albumin and glutaraldehyde provides
a strong tissue bond to seal large blood vessel
anastomoses.15 Preparation is relatively quickAORN Journal j S13
November 2012 Vol 96 No 5 NEVELEFFand use is moderately easy because this agent is
available prepackaged in applicator syringes. It
should be applied sparingly, however, to avoid
unintended tissue contact.15 Clinical trial data
suggest that BioGlue may be a viable alternative
to standard vascular repair, with a large multi-
center study reporting significantly higher rates of
hemostasis with BioGlue compared with standard
care (81% versus 57%, respectively; P < .003).41
Major adverse events with BioGlue include the
potential for tissue necrosis, nerve injury, adhe-
sive embolism, limitation of aortic growth, and
pseudoaneurysm, as well as the risk of toxicity
from glutaraldehyde.14,15,41Adhesives
Adhesives (eg, cyanoacrylates, albumin and glu-
taraldehyde, fibrin sealants) represent the final
category of hemostatic agents. These agents pro-
duce a hemostatic effect by gluing tissue surfaces
together to prevent blood loss.14,15 Similar to seal-
ants, these agents stop bleeding by preventingTable 4. Adhesives: Com
Efficacy, Usability, and C
Category Safety
Cyanoacrylate
• Octyl cyanoacrylate
• Butyl cyanoacrylate 
• Class II octyl or butyl 
cyanoacrylate ± dye and/or 
polyester mesh
• For external use only
Albumin + glutaraldehyde
• Bovine serum albumin
+ 10% glutaraldehyde
• Possible tissue injury
• Emboli
• Pseudoaneurysms 
Fibrin sealant
• Human pooled plasma
• Possible disease transmission
+ = most complex to prepare and use
++ = relatively easy to prepare and use
+++ = easiest to prepare and use
1. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: compon
S14 j AORN Journalblood leakage from vascular structures but other-
wise do not enhance clotting. Consideration of
the differences between products in this category
is important because certain adhesives may be
better suited than others for a given surgical situ-
ation (Table 4).15
Cyanoacrylates. Octyl cyanoacrylate (eg, Der-
mabondTM) and butyl cyanoacrylate (eg, Indermil,
Histoacryl, Histoacryl Blue) are for topical use
only. These agents hold skin edges together and
may also function as a barrier against bacteria.14,15
Although these products are strong adhesives, they
are best used as an adjunct with deep dermal sutures
because surface skin can tear away from the deeper
dermis layers, causing the wound to reopen.15
Cyanoacrylates are quick and easy to use, are
stored at room temperature, and are relatively
inexpensive. However, they have an exothermic
reaction when applied to the skin and thus can cause
some discomfort to patients.14,15 Safety concerns
include potential eye injury, and use on infected,
wet, or poorly healing wounds should be avoided.14parison of Safety, 
ost1
Efficacy Usability Cost
• Enhanced
• Moderate (in 
skin closure)
+++ $
• Enhanced ++ $$
• Moderate + $$
$ = least expensive
$$ =  moderately expensive
$$$ = most expensive
ents of the surgical toolbox. Transfusion. 2008;48(7):1502-1516.
NACCME SUPPLEMENT www.aornjournal.orgAlbumin and glutaraldehyde. Albumin and
glutaraldehyde (BioGlue), discussed earlier as a
sealant, is also FDA approved to be used as an
adhesive during aortic dissection for attachment of
the intimal and adventitial layers of the aorta.41 The
characteristics of this product (eg, ease of prepa-
ration and use, safety concerns) are the same when
this product is used as a sealant or as an adhesive.15
Fibrin sealant. Predominately used for attaching
skin grafts to underlying tissue layers during burn
reconstruction surgery or attaching skin flaps du-
ring facial plastic reconstructive surgery, a pooled
human plasma fibrin sealant known as ArtissTM has
been recently approved for use as an adhesive. This
agent has a lower concentration of thrombin com-
pared with other fibrin sealants, so polymerization
occurs more slowly, allowing the surgeon to care-
fully place and adjust the skin graft or flap.15,42
Compared with other adhesives, Artiss is of
moderate strength, is somewhat more complex
to prepare and use, and is relatively expensive.15CONCLUSION
Given the considerable clinical and economic
consequences of surgical bleeding and transfusions,
optimizing hemostatic practices is a critical focus
for the surgical team. Understanding the clinical
efficacy, adverse effects, ease of preparation and
use, and costs of the various topical hemostats,
sealants, and adhesives in the surgeon’s armamen-
tarium can ensure the safe, efficacious, and judi-
cious use of these agents. With knowledge of the
consequences of blood transfusions and a solid
understanding of hemostatic agents, perioperative
nurses play an essential role in reducing patient
complications as well as decreasing the costs
related to intraoperative bleeding. Perioperative
nurses are uniquely qualified to influence the
selection of hemostats available in the operating
suite. Perioperative nurses typically work with
a variety of surgeons in different specialties so
they are well positioned to develop considerable
practical knowledge regarding the efficacy andappropriate application of hemostatic agents and
thus have a positive effect on clinical outcomes
and costs.
Editor’s note: Gelfoam and Gelfoam Plus are re-
gistered trademarks of Pfizer, New York, NY. Sur-
gicel Fibrillar and Dermabond are trademarks and
Surgifoam, Surgicel, Surgicel Nu-Knit, Evithrom,
and Evicel are registered trademarks of Ethicon,
Inc, West Sommerville, NJ. Avitene sheets and
Avitene Ultrafoam collagen sponges are trade-
marks of Bard Davol, Warwick, RI. Arısta is a
registered trademark and Vitasure is a trademark
of Medafor, Minneapolis, MN. Hemostase MPH
and BioGlue are registered trademarks of Cry-
oLife, Kennesaw, GA. Thrombin-JMI is a regis-
tered trademark of King Pharmaceuticals, Bristol,
TN. Recothrom is a registered trademark of
ZymoGenetics, Seattle, WA. Surgiflo is a registered
trademark of Ethicon, Inc, West Sommerville, NJ.
Floseal is a registered trademark and Tisseel and
Artiss are trademarks of Baxter Healthcare Corp,
Deerfield, IL. Vitagel is a trademark of Orthovita,
Inc, Malvern, PA. DuraSeal is a trademark of
Covidien, Mansfield, MA. Coseal is a registered
trademark of Baxter Healthcare Corp, Deerfield,
IL. Progel is a registered trademark of NeoMend,
Inc, Irvine, CA. Indermil is a registered trademark
of Syneture, Norwalk, CT. Histoacryl and Histo-
acryl Blue are registered trademarks of TissueSeal,
LLC, Ann Arbor, MI.References
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